ARMATA PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -0.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-25
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -0.10%.
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -3.70%.
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -1.60%.
- ARMATA PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.10% 10-K · filed 2026-03-25 | |
| 2024-12-31 | -3.70% 10-K · filed 2026-03-25 | |
| 2023-12-31 | -1.60% 10-K · filed 2025-03-21 | |
| 2022-12-31 | -0.20% 10-K · filed 2024-03-21 | |
| 2021-12-31 | -0.80% 10-K · filed 2023-03-16 | |
| 2020-12-31 | -0.70% 10-K · filed 2022-03-17 | |
| 2019-12-31 | -0.50% 10-K · filed 2021-03-18 | |
| 2018-12-31 | 0.00% 10-K · filed 2020-03-19 | -0.30% 10-K · filed 2019-03-25 |
| 2017-12-31 | -1.00% 10-K · filed 2019-03-25 | |
| 2016-12-31 | -0.60% 10-K · filed 2018-03-14 | |
| 2015-12-31 | -138.20% 10-K · filed 2017-03-27 | |
| 2014-12-31 | -54.90% 10-K · filed 2015-04-15 | |
| 2013-12-31 | -24.80% 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |